Wealthfront Advisers LLC Purchases 4,348 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Wealthfront Advisers LLC raised its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 19.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,180 shares of the company’s stock after buying an additional 4,348 shares during the quarter. Wealthfront Advisers LLC’s holdings in GE HealthCare Technologies were worth $2,125,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Ashton Thomas Securities LLC acquired a new position in shares of GE HealthCare Technologies during the 3rd quarter worth about $26,000. Darwin Wealth Management LLC acquired a new position in shares of GE HealthCare Technologies during the 3rd quarter worth about $31,000. Continuum Advisory LLC grew its position in shares of GE HealthCare Technologies by 101.8% during the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after buying an additional 168 shares during the period. Bank of Jackson Hole Trust acquired a new position in shares of GE HealthCare Technologies during the 4th quarter worth about $32,000. Finally, OFI Invest Asset Management acquired a new position in shares of GE HealthCare Technologies during the 4th quarter worth about $34,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and boosted their target price for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. Citigroup boosted their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Wells Fargo & Company boosted their price objective on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Finally, The Goldman Sachs Group upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $100.00 in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.75.

GE HealthCare Technologies Trading Up 0.6 %

NASDAQ:GEHC opened at $81.97 on Friday. GE HealthCare Technologies Inc. has a twelve month low of $74.51 and a twelve month high of $94.80. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The business has a 50 day moving average price of $87.26 and a two-hundred day moving average price of $86.10. The company has a market cap of $37.48 billion, a P/E ratio of 18.93, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The firm had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.33 billion. As a group, analysts expect that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.